Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Cybin Inc. Common Shares (CYBN)
Company Research
Source: Yahoo! Finance
analog in development for the adjunctive treatment of Major Depressive Disorder ("MDD") - - Clinical site selection complete for Phase 3 multinational study of CYB003, which is expected to begin in summer 2024 - - Cash totaled C$209 million as of March 31, 2024 - - Initiated a Phase 2 study of CYB004, its proprietary deuterated dimethyltryptamine ("DMT") program in development for the treatment of Generalized Anxiety Disorder ("GAD") - - Strengthened intellectual property portfolio with more than 60 granted patents and over 200 pending applications - - Closed oversubscribed private placement of U.S.$150 million (the "Private Placement") led by a syndicate of leading biopharmaceutical institutional investors - This news release constitutes a "designated news release" for the purposes of Cybin's prospectus supplements each dated August 23, 2023, to its short form base shelf prospectus dated August 17, 2023, as amended December 22, 2023 and April 8, 2024. TORONTO, June 26,
Show less
Read more
Impact Snapshot
Event Time:
CYBN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYBN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYBN alerts
High impacting Cybin Inc. Common Shares news events
Weekly update
A roundup of the hottest topics
CYBN
News
- What Makes Cybin Inc. (CYBN) a New Buy Stock [Yahoo! Finance]Yahoo! Finance
- Cybin Reports Fiscal Year 2024 Financial Results and Recent Business HighlightsBusiness Wire
- Cybin Inc. (NYSE: CYBN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference [Yahoo! Finance]Yahoo! Finance
- Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceBusiness Wire
CYBN
Earnings
- 6/26/24 - Miss
CYBN
Sec Filings
- 6/27/24 - Form 6-K/A
- 6/26/24 - Form 6-K
- 6/26/24 - Form 40-F
- CYBN's page on the SEC website